A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Trial Details

NCT ID
NCT07503808
Phase
PHASE1
Sponsor
IDEAYA Biosciences
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • IDE034
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Lake Success, New York, United States|40.77066,-73.71763
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Participant must be at least 18 years of age or the age of maturity per local regulations
  • Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial ca…
  • Archival tissue sample for testing
  • Measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →